Eledon Pharmaceuticals (ELDN) Preferred Stock Liabilities (2013 - 2026)

Eledon Pharmaceuticals' Preferred Stock Liabilities history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• Quarterly Preferred Stock Liabilities changed 0.0% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (changed 0.0% YoY) and the FY2025 annual result came in at $2.2 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities was $2.2 million for Q1 2026 at Eledon Pharmaceuticals, roughly flat from $2.2 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $53.5 million in Q4 2023 and bottomed at $2.2 million in Q2 2024.
• A 5-year average of $11.6 million and a median of $2.2 million in 2024 frame the typical range for Preferred Stock Liabilities.
• Annual changes were most pronounced in 2023 — Preferred Stock Liabilities soared 1674.71% — and 2024, when it sank 95.98%.
• Eledon Pharmaceuticals' Preferred Stock Liabilities stood at $3.0 million in 2022, then surged by 1674.71% to $53.5 million in 2023, then sank by 95.98% to $2.2 million in 2024, then changed by 0.0% to $2.2 million in 2025, then changed by 0.0% to $2.2 million in 2026.
• Business Quant data shows ELDN's Preferred Stock Liabilities at $2.2 million in Q1 2026, $2.2 million in Q4 2025, and $2.2 million in Q3 2025.